AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7801862 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of diltiazem
Number of subjects: 84
Study 2237752 — intervention group
Group type: COMPARATOR
Intervention: 10 Gy irradiation
Number of subjects: 44
Study 2237752 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy irradiation
Number of subjects: 44
Study 4392983 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (200 to 600 mg b.d.)
Number of subjects: 15
Study 4392983 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg q.d.s.)
Number of subjects: 15
Study 31274345 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea (EVH) in the morning (AM)
Number of subjects: 23
Study 31274345 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea (EVH) in the evening (PM)
Number of subjects: 23
Study 31274345 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FEV1 before AM tests
Number of subjects: 23
Study 31274345 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FEV1 before PM tests
Number of subjects: 23
Study 31274345 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute ventilation in AM tests
Number of subjects: 23
Study 31274345 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute ventilation in PM tests
Number of subjects: 23
Study 31274345 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 30522886 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP therapy
Number of subjects: 25
Study 30522886 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study 29114763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary instruction
Number of subjects: 241
Study 29114763 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 241
Study 26176342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 264
Study 26176342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 24479361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg (2 ml), intravenous injection, twice a day
Number of subjects: 56
Study 24479361 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 ml, intravenous injection, twice a day (Control)
Number of subjects: 56
Study 21263210 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle baby massage
Number of subjects: 42
Study 21263210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 42
Study 19385962 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 98
Study 19385962 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 98
Study 16785142 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1.5 g/day + rFSH 150 UI/day + GnRH antagonist 0.25 mg/day
Number of subjects: 40
Study 15116994 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐shaped masking functions
Number of subjects: 0
Study 15116994 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotonic masking functions
Number of subjects: 0
Study 15116994 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental situation
Number of subjects: 0
Study 11357500 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 MBq DW-166HC
Number of subjects: 16
Study 11357500 — intervention group
Group type: EXPERIMENTAL
Intervention: 555 MBq DW-166HC
Number of subjects: 16
Study 11357500 — intervention group
Group type: EXPERIMENTAL
Intervention: 740 MBq DW-166HC
Number of subjects: 16
Study 9408319 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (three field lymphadenectomy for esophageal cancer, D2 lymphadenectomy for gastric cancer)
Number of subjects: 25
Study 9408319 — intervention group
Group type: COMPARATOR
Intervention: Limited lymphadenectomy (D1)
Number of subjects: 25
Study 8231902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine oestrogens (CEE) cyclically (n = 16)
Number of subjects: 90
Study 8231902 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/day transdermal oestradiol (E2) cyclically (n = 20)
Number of subjects: 90
Study 8231902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE continuously (n = 15)
Number of subjects: 90
Study 8231902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE and 2.5 mg/day of MPA continuously (n = 20)
Number of subjects: 90
Study 8231902 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 90
Study 3475969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1,000 mg
Number of subjects: 0
Study 3475969 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 0
Study 31444866 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple emulsion loaded with Sphaeranthus indicus flower extract
Number of subjects: 0
Study 29105855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin 1 g three times daily for 10 days
Number of subjects: 12
Study 29105855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin exposure in primary hepatocytes for 48 h
Number of subjects: 12
Study 27259062 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 84
Study 27259062 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 84
Study 24879757 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilpaterol hydrochloride (ZH; 8.3 mg/kg of DM for 20 d with 3‐d withdrawal)
Number of subjects: 1914
Study 24879757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RH; 308 mg·head(‐1)·d(‐1) for 28 d)
Number of subjects: 1914
Study 24879757 — intervention group
Group type: COMPARATOR
Intervention: No βAA (CON)
Number of subjects: 1914
Study 24879757 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer assessment of eating quality (n = 400; 200/postmortem aging period)
Number of subjects: 1914
Study 23577826 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Number of subjects: 44
Study 23577826 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (CM)
Number of subjects: 44
Study 23577826 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR
Number of subjects: 44
Study 23577826 — intervention group
Group type: COMPARATOR
Intervention: CM
Number of subjects: 44
Study 20488971 — intervention group
Group type: EXPERIMENTAL
Intervention: Especially for Daughters intervention (audio CDs mailed home)
Number of subjects: 268
Study 20488971 — intervention group
Group type: COMPARATOR
Intervention: Attention-controlled condition (print materials)
Number of subjects: 268
Study 20488971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 19026795 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative renal dysfunction
Number of subjects: 3014
Study 19026795 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative renal dysfunction)
Number of subjects: 3014
Study 16125252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionized, processed silicone tubes
Number of subjects: 46
Study 16125252 — intervention group
Group type: COMPARATOR
Intervention: Silicone tubes
Number of subjects: 46
Study 16125252 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ventilation tube application
Number of subjects: 46
Study 16125252 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm growth
Number of subjects: 46
Study 15070409 — intervention group
Group type: EXPERIMENTAL
Intervention: Veteran group (36 residents)
Number of subjects: 81
Study 15070409 — intervention group
Group type: COMPARATOR
Intervention: Non-veteran group (45 residents)
Number of subjects: 81
Study 11412729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 60
Study 11412729 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 60
Study 9008250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride supplementation (100 mmol/24 h)
Number of subjects: 99
Study 9008250 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride restriction (60 to 80 mmol/24 h)
Number of subjects: 99
Study 9008250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum sodium chloride
Number of subjects: 99
Study 9008250 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride restriction
Number of subjects: 99
Study 9008250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride supplementation
Number of subjects: 99
Study 9008250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride restriction (open-label)
Number of subjects: 99
Study 9008250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride ad libitum (open-label)
Number of subjects: 99
Study 8509523 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (MAO inhibitor), fixed-dose schedule for 4 weeks
Number of subjects: 26
Study 8509523 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 3620290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (1 mg, 10 mg, 50 mg)
Number of subjects: 0
Study 3620290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (chronic treatment)
Number of subjects: 0
Study 3620290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30827283 — intervention group
Group type: EXPERIMENTAL
Intervention: CATH TAG electronic reminder system
Number of subjects: 1167
Study 30827283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CATH TAG)
Number of subjects: 1167
Study 29379865 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at 20 Hz on the left prefrontal area
Number of subjects: 0
Study 29379865 — intervention group
Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) at 5 Hz, 10 Hz, and 40 Hz
Number of subjects: 0
Study 25601623 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-moment non-invasive neurostimulation (MNNS)
Number of subjects: 33
Study 25601623 — intervention group
Group type: COMPARATOR
Intervention: International Affective Pictures System (IAPS)
Number of subjects: 33
Study 24061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral intervention (5-week duration)
Number of subjects: 228
Study 24061387 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 228
Study 24061387 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral intervention
Number of subjects: 228
Study 21420678 — intervention group
Group type: EXPERIMENTAL
Intervention: IKH‐01 (0.035 mg ethinyl estradiol and 1 mg norethisterone)
Number of subjects: 115
Study 21420678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 21420678 — intervention group
Group type: EXPERIMENTAL
Intervention: IKH‐01
Number of subjects: 115
Study 19439099 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for children (KIDNET)
Number of subjects: 31
Study 19439099 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation-relaxation (MED-RELAX)
Number of subjects: 31
Study 16890599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 72 weeks (group B)
Number of subjects: 326
Study 16890599 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 48 weeks (group A)
Number of subjects: 326
Study 16890599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a plus ribavirin for 24 weeks (group C)
Number of subjects: 326
Study 16890599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a plus ribavirin for 48 weeks (group D)
Number of subjects: 326
Study 16890599 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alfa2a plus ribavirin for 72 weeks (group B) in genotype 1-infected patients
Number of subjects: 326
Study 16890599 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alfa2a plus ribavirin for 48 weeks (group A) in genotype 1-infected patients
Number of subjects: 326
Study 15083371 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal fatigue protocol (20% MVC) in men
Number of subjects: 20
Study 15083371 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal fatigue protocol (20% MVC) in women
Number of subjects: 20
Study 15083371 — intervention group
Group type: COMPARATOR
Intervention: Comparison between genders
Number of subjects: 20
Study 11473066 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 217
Study 11473066 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 217
Study 11473066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 9778330 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography with E/Ea ratio
Number of subjects: 100
Study 9778330 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 100
Study 7611921 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg tid
Number of subjects: 18
Study 7611921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg tid
Number of subjects: 18
Study 7611921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 3234469 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (50 mg b.d. for 15 days)
Number of subjects: 8
Study 3234469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (50 mg b.d. for 15 days)
Number of subjects: 8
Study 3234469 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (1 g/kg)
Number of subjects: 8
Study 3234469 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (Maprotiline and Nomifensine)
Number of subjects: 8
Study 3234469 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 8
Study 29948023 — intervention group
Group type: COMPARATOR
Intervention: INTP5 (3 mg/0.3 ml)
Number of subjects: 344
Study 29948023 — intervention group
Group type: COMPARATOR
Intervention: INTP5 (6 mg/0.6 ml)
Number of subjects: 344
Study 29948023 — intervention group
Group type: EXPERIMENTAL
Intervention: Neulasta (3 mg/0.3 ml)
Number of subjects: 344
Study 29948023 — intervention group
Group type: EXPERIMENTAL
Intervention: Neulasta (6 mg/0.6 ml)
Number of subjects: 344
Study 29948023 — intervention group
Group type: COMPARATOR
Intervention: INTP5
Number of subjects: 344
Study 29948023 — intervention group
Group type: EXPERIMENTAL
Intervention: Neulasta
Number of subjects: 344
Study 29948023 — intervention group
Group type: COMPARATOR
Intervention: INTP5 and Neulasta
Number of subjects: 344
Study 26515228 — intervention group
Group type: COMPARATOR
Intervention: Sleeping-bags
Number of subjects: 80
Study 26515228 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 80
Study 23605244 — intervention group
Group type: EXPERIMENTAL
Intervention: TLLS+ (transmeatal low-power laser stimulation at 5 mW, 650 nM wavelength for 20 min daily and oral betahistine 24 mg twice per day for 10 weeks)
Number of subjects: 43
Study 23605244 — intervention group
Group type: COMPARATOR
Intervention: TLLS- (placebo device and oral betahistine 24 mg twice per day for 10 weeks)
Number of subjects: 43
Study 23605244 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TLLS+ and TLLS- groups
Number of subjects: 43
Study 22874110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 50
Study 22874110 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaC)
Number of subjects: 50
Study 19838644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cerebral microembolization during THA
Number of subjects: 45
Study 18513916 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice invitation based on General Medical Council guidelines and combined with a decisional balance sheet
Number of subjects: 417
Study 18513916 — intervention group
Group type: COMPARATOR
Intervention: Traditional invitation
Number of subjects: 417
Study 18513916 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 417
Study 16193258 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole and minocycline (100 mg i.d.)
Number of subjects: 20
Study 16193258 — intervention group
Group type: COMPARATOR
Intervention: Riluzole (50 mg b.i.d.)
Number of subjects: 20
Study 12901286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MU alpha N1‐IFN daily for 10 days every 3 months
Number of subjects: 20
Study 12901286 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 20
Study 12901286 — intervention group
Group type: COMPARATOR
Intervention: Reduced dosage of alpha N1‐IFN or stopped interferon therapy or received 30MU dose at 6‐month intervals
Number of subjects: 20
Study 10028075 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (750 mg loading dose followed by 250 mg/d)
Number of subjects: 300
Study 10028075 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/d)
Number of subjects: 300
Study 10028075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8684870 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand erythromycin estolate
Number of subjects: 42
Study 8684870 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand trimethoprim‐sulfamethoxazole
Number of subjects: 42
Study 8684870 — intervention group
Group type: COMPARATOR
Intervention: Generic cephalexin
Number of subjects: 42
Study 8684870 — intervention group
Group type: COMPARATOR
Intervention: Generic erythromycin ethylsuccinate/sulfisoxazole
Number of subjects: 42
Study 8684870 — intervention group
Group type: COMPARATOR
Intervention: Generic penicillin V potassium
Number of subjects: 42
Study 1830321 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH‐(1‐24) stimulation
Number of subjects: 21
Study 6882332 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% O2
Number of subjects: 6
Study 6882332 — intervention group
Group type: EXPERIMENTAL
Intervention: 13% O2
Number of subjects: 6
Study 6882332 — intervention group
Group type: COMPARATOR
Intervention: 21%, 19%, 17% O2
Number of subjects: 6
Study 6882332 — intervention group
Group type: EXPERIMENTAL
Intervention: 15%, 13% O2
Number of subjects: 6
Study 31835477 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (SuperFIT)
Number of subjects: 0
Study 31835477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29419337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha Yoga intervention (twice‐weekly, 60‐minute sessions for 8 weeks)
Number of subjects: 10
Study 27449643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (monthly or every 2 months after 3 monthly injections)
Number of subjects: 843
Study 27449643 — intervention group
Group type: COMPARATOR
Intervention: Monthly ranibizumab
Number of subjects: 843
Study 27449643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes
Number of subjects: 843
Study 27449643 — intervention group
Group type: EXPERIMENTAL
Intervention: Study eyes
Number of subjects: 843
Study 27449643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes and study eyes
Number of subjects: 843
Study 25455833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 199
Study 25455833 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 199
Study 25455833 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 199
Study 23469597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dujieqing Oral Liquid (DJQ) combined with conventional chemotherapy (20 mL each time, three times daily for 8 weeks)
Number of subjects: 60
Study 23469597 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 60
Study 23469597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dujieqing Oral Liquid (DJQ) combined with conventional chemotherapy
Number of subjects: 60
Study 19861364 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed awareness patients (n=7)
Number of subjects: 38
Study 19861364 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=25)
Number of subjects: 38
Study 18030066 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60-mg loading dose (LD) followed by 10-mg daily maintenance dose (MD)
Number of subjects: 41
Study 18030066 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60-mg
Number of subjects: 41
Study 18030066 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10-mg MD
Number of subjects: 41
Study 18030066 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600-mg
Number of subjects: 41
Study 15649107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 60
Study 15649107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12576937 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict normalization of blood glucose (80‐110 mg/dL) with insulin infusion
Number of subjects: 1548
Study 12576937 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (blood glucose levels at 180‐200 mg/dL)
Number of subjects: 1548
Study 10697394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin binding to erythrocyte receptors in patients with essential hypertension
Number of subjects: 23
Study 10697394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin concentration in patients with essential hypertension
Number of subjects: 23
Study 10697394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degradation by erythrocytes
Number of subjects: 23
Study 10697394 — intervention group
Group type: COMPARATOR
Intervention: Correlation between body weight and insulin concentration
Number of subjects: 23
Study 8605753 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 270 mgI/ml
Number of subjects: 150
Study 8605753 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate 320 mgI/ml
Number of subjects: 150
Study 1911585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg orally 30 h before termination of pregnancy
Number of subjects: 80
Study 1911585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1911585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 80